Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HRMY NASDAQ:IDYA NASDAQ:OCUL NASDAQ:SAGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHRMYHarmony Biosciences$35.99-0.9%$35.47$26.47▼$41.61$2.07B0.84494,329 shs742,372 shsIDYAIDEAYA Biosciences$27.16+5.1%$23.66$13.45▼$37.99$2.38B0.12909,753 shs1.64 million shsOCULOcular Therapeutix$13.60+7.1%$11.68$5.78▼$13.85$2.37B1.52.01 million shs4.98 million shsSAGESage Therapeutics$8.68$8.88$4.62▼$11.44$543.54M0.263.63 million shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHRMYHarmony Biosciences-0.85%-2.44%+3.81%+1.10%-0.14%IDYAIDEAYA Biosciences+5.15%+10.63%+14.94%+24.99%-29.44%OCULOcular Therapeutix+7.09%+11.38%+8.80%+50.78%+61.33%SAGESage Therapeutics0.00%0.00%0.00%+26.72%+8.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHRMYHarmony Biosciences$35.99-0.9%$35.47$26.47▼$41.61$2.07B0.84494,329 shs742,372 shsIDYAIDEAYA Biosciences$27.16+5.1%$23.66$13.45▼$37.99$2.38B0.12909,753 shs1.64 million shsOCULOcular Therapeutix$13.60+7.1%$11.68$5.78▼$13.85$2.37B1.52.01 million shs4.98 million shsSAGESage Therapeutics$8.68$8.88$4.62▼$11.44$543.54M0.263.63 million shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHRMYHarmony Biosciences-0.85%-2.44%+3.81%+1.10%-0.14%IDYAIDEAYA Biosciences+5.15%+10.63%+14.94%+24.99%-29.44%OCULOcular Therapeutix+7.09%+11.38%+8.80%+50.78%+61.33%SAGESage Therapeutics0.00%0.00%0.00%+26.72%+8.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHRMYHarmony Biosciences 3.00Buy$51.0041.71% UpsideIDYAIDEAYA Biosciences 2.80Moderate Buy$45.7768.52% UpsideOCULOcular Therapeutix 3.00Buy$17.2026.47% UpsideSAGESage Therapeutics 1.93Reduce$7.85-9.56% DownsideCurrent Analyst Ratings BreakdownLatest SAGE, IDYA, OCUL, and HRMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025IDYAIDEAYA BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy ➝ Outperform9/4/2025IDYAIDEAYA BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$41.009/4/2025IDYAIDEAYA BiosciencesBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$40.009/4/2025IDYAIDEAYA BiosciencesBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$40.009/4/2025IDYAIDEAYA BiosciencesCitizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated Coverage$41.009/3/2025IDYAIDEAYA BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$72.00 ➝ $74.008/6/2025OCULOcular TherapeutixScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Outperform$22.00 ➝ $20.008/5/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $15.007/28/2025IDYAIDEAYA BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$66.00 ➝ $72.007/22/2025IDYAIDEAYA BiosciencesTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy7/21/2025HRMYHarmony BiosciencesTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$48.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHRMYHarmony Biosciences$714.73M2.90$2.95 per share12.21$11.56 per share3.11IDYAIDEAYA Biosciences$7M340.06N/AN/A$12.25 per share2.22OCULOcular Therapeutix$63.72M37.14N/AN/A$2.01 per share6.77SAGESage Therapeutics$41.24M13.18N/AN/A$5.89 per share1.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHRMYHarmony Biosciences$145.49M$3.1011.6111.570.4223.44%26.34%17.71%11/4/2025 (Estimated)IDYAIDEAYA Biosciences-$274.48M-$3.79N/AN/AN/AN/A-31.42%-29.45%11/3/2025 (Estimated)OCULOcular Therapeutix-$193.51M-$1.28N/AN/AN/A-382.51%-71.92%-49.36%11/13/2025 (Estimated)SAGESage Therapeutics-$400.67M-$4.89N/AN/AN/A-427.78%-67.10%-58.42%11/4/2025 (Estimated)Latest SAGE, IDYA, OCUL, and HRMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025HRMYHarmony Biosciences$0.78$0.68-$0.10$0.68$204.37 million$200.49 million8/5/2025Q2 2025IDYAIDEAYA Biosciences-$0.85-$0.88-$0.03-$0.88$3.48 million$6.00 million8/5/2025Q2 2025OCULOcular Therapeutix-$0.35-$0.39-$0.04-$0.39$13.12 million$13.46 million7/30/2025Q2 2025SAGESage Therapeutics-$0.96-$0.79+$0.17-$0.79$16.69 million$31.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHRMYHarmony BiosciencesN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ASAGESage TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHRMYHarmony Biosciences0.203.843.80IDYAIDEAYA BiosciencesN/A12.3912.39OCULOcular Therapeutix0.2310.1010.02SAGESage TherapeuticsN/A9.169.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHRMYHarmony Biosciences86.23%IDYAIDEAYA Biosciences98.29%OCULOcular Therapeutix59.21%SAGESage Therapeutics99.22%Insider OwnershipCompanyInsider OwnershipHRMYHarmony Biosciences23.60%IDYAIDEAYA Biosciences2.50%OCULOcular Therapeutix2.30%SAGESage Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHRMYHarmony Biosciences20057.53 million43.96 millionOptionableIDYAIDEAYA Biosciences8087.64 million85.45 millionOptionableOCULOcular Therapeutix230173.99 million169.99 millionOptionableSAGESage Therapeutics69062.62 million59.18 millionOptionableSAGE, IDYA, OCUL, and HRMY HeadlinesRecent News About These CompaniesSage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric PortfolioSeptember 2, 2025 | finance.yahoo.comSage Therapeutics, Inc. (NASDAQ:SAGE) Receives $7.85 Consensus PT from AnalystsAugust 28, 2025 | americanbankingnews.comUK Regulator Approves Biogen’s Drug For Treating Postnatal DepressionAugust 27, 2025 | msn.comReunion’s psychedelic drug headed to late-stage testingAugust 18, 2025 | yahoo.comWhy Are Supernus Pharmaceuticals (SUPN) Shares Soaring TodayAugust 6, 2025 | finance.yahoo.comSage (SAGE) Q2 Revenue Jumps 264%August 1, 2025 | aol.comASupernus strengthens neuropsychiatric portfolio with Sage TherapeuticsAugust 1, 2025 | finance.yahoo.comSage Therapeutics Announces Second Quarter 2025 Financial ResultsJuly 31, 2025 | finance.yahoo.comSage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue EstimatesJuly 30, 2025 | zacks.comEurope's CHMP gives thumbs up to Lilly's Kisunla and Gilead's long-acting PrEP drug YeytuoJuly 25, 2025 | fiercepharma.comFSAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGEJuly 14, 2025 | businesswire.comBeyond The Numbers: 6 Analysts Discuss Sage Therapeutics StockJuly 9, 2025 | nasdaq.comScotiabank Downgrades Sage Therapeutics (SAGE)July 9, 2025 | msn.comRx Rundown: AbbVie, Healthline, Beckley Psytech and moreJuly 3, 2025 | mmm-online.comMSage’s Search for Lifeline Ran Into Defiant Biogen CEOJuly 3, 2025 | biospace.comBM&A ramped up in June, with blueBird, Sage and Snyk tie-upsJuly 2, 2025 | bizjournals.comBoston-area pharma company to lay off entire 300-person staff after saleJuly 1, 2025 | msn.com$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Sage Therapeutics, Inc. (NASDAQ: SAGE)July 1, 2025 | globenewswire.comWhat Makes Sage Therapeutics (SAGE) a New Buy StockJuly 1, 2025 | zacks.comSage Therapeutics cuts most of its workforce following acquisitionJuly 1, 2025 | statnews.comSNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSAGE, IDYA, OCUL, and HRMY Company DescriptionsHarmony Biosciences NASDAQ:HRMY$35.99 -0.31 (-0.85%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$36.26 +0.27 (+0.74%) As of 09/5/2025 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.IDEAYA Biosciences NASDAQ:IDYA$27.16 +1.33 (+5.15%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$27.68 +0.52 (+1.93%) As of 09/5/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Ocular Therapeutix NASDAQ:OCUL$13.60 +0.90 (+7.09%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$13.65 +0.05 (+0.38%) As of 09/5/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Sage Therapeutics NASDAQ:SAGESage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
